



Published in final edited form as:

Nature. 2013 May 2; 497(7447): 67–73. doi:10.1038/nature12113.

Integrated Genomic Characterization of Endometrial Carcinoma

The Cancer Genome Atlas Research Network

Summary

We performed an integrated genomic, transcriptomic, and proteomic characterization of 373 endometrial carcinomas using array- and sequencing-based technologies. Uterine serous tumors and ~25% of high-grade endometrioid tumors have extensive copy number alterations, few DNA methylation changes, low ER/PR levels, and frequent *TP53* mutations. Most endometrioid tumors have few copy number alterations or *TP53* mutations but frequent mutations in *PTEN*, *CTNNB1*, *PIK3CA*, *ARID1A*, *KRAS* and novel mutations in the SWI/SNF gene *ARID5B*. A subset of endometrioid tumors we identified had a dramatically increased transversion mutation frequency, and newly identified hotspot mutations in *POLE*. Our results classified endometrial cancers into four categories: *POLE* ultramutated, microsatellite instability hypermutated, copy number low, and copy number high. Uterine serous carcinomas share genomic features with ovarian serous and basal-like breast carcinomas. We demonstrated that the genomic features of endometrial carcinomas permit a reclassification that may impact post-surgical adjuvant treatment for women with aggressive tumors.

Endometrial cancer arises from the lining of the uterus. It is the fourth most common malignancy among women in the United States, with an estimated 47,000 new cases and

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence and requests for materials should be addressed to D. Levine (levine2@mskcc.org).

The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper.

Reprints and permissions information is available at www.nature.com/reprints. This paper is distributed under the terms of the Creative Commons Attribution-Non-Commercial-Share Alike license, and the online version of the paper is freely available to all readers.

Author Contributions

The TCGA research network contributed collectively to this study. Biospecimens were provided by the tissue source sites and processed by the biospecimen core resource. Data generation and analyses were performed by the genome sequencing centers, cancer genome characterization centers and genome data analysis centers. All data were released through the data coordinating center. The National Cancer Institute and National Human Genome Research Institute project teams coordinated project activities. We also acknowledge the following TCGA investigators who made substantial contributions to the project: N.S. (manuscript coordinator); J.G. (data coordinator); C.K. and L.D. (DNA sequence analysis); W.Z. and Y.L. (mRNA sequence analysis); H.S. and P.W.L. (DNA methylation analysis); A.D.C., I.P. (copy number analysis); S.L. and A.H. (translocations); N.S., N.W. G.C., C.B. and C.Y. (pathway analysis); A.C. and A.G.R. (miRNA sequence analysis); R.B., P.J.G., G.B.M. and R.A.S. (pathology and clinical expertise); G.B.M. H.L. R.A. (reverse phase protein arrays); P.J.G. and R.B. (disease experts); G.B.M., and R.K. (manuscript editing); D.A.L. and E.R.M. (project chairs).

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

The Cancer Genome Atlas Research Network (Participants are arranged by area of contribution and then by institution.) See author list in excel spreadsheet.

The primary and processed data used to generate the analyses presented here are deposited at the Data Coordinating Center (<https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp>); all of the primary sequence files are deposited in CGHub (<https://cghub.ucsc.edu/>). Sample lists, data matrices and supporting data can be found at: https://tcga-data.nci.nih.gov/docs/publications/ucec_2013/). The data can be explored via the cBio Cancer Genomics Portal (<http://cbiportal.org>).

8,000 deaths in 2012.¹ Most patients present with low-grade, early-stage disease. The majority of patients with more aggressive, high-grade tumors who have disease spread beyond the uterus will progress within 1 year.^{2,3} Endometrial cancers have been broadly classified into two groups.⁴ Type I endometrioid tumors are linked to estrogen excess, obesity, hormone-receptor positivity, and favorable prognosis compared with type II, primarily serous, tumors that are more common in older, non-obese women and have worse outcome. Early-stage endometrioid cancers are often treated with adjuvant radiotherapy, whereas serous tumors are treated with chemotherapy, similar to advanced-stage cancers of either histologic subtype. Therefore, proper subtype classification is critical for selecting appropriate adjuvant therapy.

Several prior reports suggest that *PTEN* mutations occur early in the neoplastic process of Type I tumors and co-exist frequently with other mutations in the PI3K/AKT pathway.^{5,6} Other commonly mutated genes in Type I tumors include *FGFR2*, *ARID1A*, *CTNNB1*, *PIK3CA*, *PIK3RI*, and *KRAS*.⁷⁻⁹ Microsatellite instability (MSI) is found in approximately one-third of Type I tumors but is infrequent in Type II tumors.¹⁰ *TP53*, *PIK3CA*, and *PPP2R1A* mutations are frequent in Type II tumors.^{11,12} Most of these studies have been limited to DNA sequencing only with samples of heterogeneous histologic subtypes and tumor grades. We present a comprehensive, multiplatform analysis of 373 endometrial carcinomas including low-grade endometrioid, high-grade endometrioid, and serous carcinomas. This integrated analysis provides key molecular insights into tumor classification, which may have direct impact on treatment recommendations for patients, and provides opportunities for genome-guided clinical trials and drug development.

Results

Tumor samples and corresponding germline DNA were collected from 373 patients, including 307 endometrioid and 66 serous (53) or mixed histology (13) cases. Local institutional review boards approved all tissue acquisition. The clinical and pathologic characteristics of the samples generally reflect a cross-section of individuals with recurrent endometrial cancer (Supplementary Table 1.1).^{2,3} The median follow-up of the cohort was 32 months (range, 1–195 months); 21% of the patients have recurred, and 11% have died. Comprehensive molecular analyses were performed at independent centers using six genomic or proteomic platforms (Supplementary Table 1.2). MSI testing performed on all samples using seven repeat loci (Supplementary Table 1.3) found MSI in 40% of endometrioid tumors and 2% of serous tumors.

Somatic copy number alterations

Somatic copy number alterations (SCNAs) were assessed in 363 endometrial carcinomas. Unsupervised hierarchical clustering grouped the tumors into four clusters (Fig. 1a). The first three copy number clusters were composed almost exclusively (97%) of endometrioid tumors without significant differences in tumor grades. Cluster 1 tumors were nearly devoid of broad SCNAs, averaging less than 0.5% genome alteration, with no significant recurrent events. Cluster 1 tumors also had significantly elevated non-synonymous mutation rates compared to all others (median 7.2×10^{-6} vs. 1.7×10^{-6} mutations per megabase (Mb),

$P < 0.001$). Copy number clusters 2 and 3 consisted mainly of endometrioid tumors, distinguished by more frequent 1q amplification in cluster 3 than cluster 2 (100% of cluster 3 tumors vs. 33% of cluster 2 tumors) and worse progression-free survival (PFS, $P = 0.003$, log-rank vs. clusters 1 and 2; Fig. 1b).

Most of the serous (50 of 53 [94%]) and mixed histology tumors (8 of 13 [62%]) clustered with 36 (12%) of the 289 endometrioid tumors, including 24% of grade 3 and 5% of grade 1 or 2, into copy number cluster 4; a single group characterized by a very high degree of copy-number alterations (Supplementary Fig. 2.1; focal SCNAs with FDR < 0.15 , and Supplementary Data File 2.1). Cluster 4 tumors were characterized by significantly recurrent previously reported focal amplifications of the oncogenes *MYC* (8q24.12), *ERBB2* (17q12), and *CCNE1* (19q12),¹³ and by SCNAs previously unreported in endometrial cancers including those containing *FGFR3* (4p16.3) and *SOX17* (8q11.23). Cluster 4 tumors also had frequent *TP53* mutations (90%), little MSI (6%), and fewer *PTEN* mutations (11%) than other endometrioid tumors (84%). Overall, these findings suggest that a subset of endometrial tumors contain distinct patterns of SCNAs and mutations that do not correlate with traditional tumor histology or grade.

As expected, tumors in the ‘serous-like’ cluster (cluster 4) had significantly worse PFS than tumors in the endometrioid cluster groups ($P = 0.003$, log-rank, Fig. 1b). Potential therapeutically relevant SCNAs included the cluster 2 15q26.2 focal amplification, which contained *IGF1R*; and cluster 4 amplifications of *ERBB2*, *FGFR1*, *FGFR3*, and *LRP1B* deletion, which was recently associated with resistance to liposomal doxorubicin in serous ovarian cancer.¹⁴

Exome sequence analysis

We sequenced the exomes of 248 tumor/normal pairs. Based on a combination of somatic nucleotide substitutions, MSI, and SCNA, the endometrial tumors were classified into four groups (Fig. 2a and b): 1) an ultra-mutated group with unusually high mutation rates (232×10^{-6} mutations/Mb) and a unique nucleotide change spectrum; 2) a hypermutated group (18×10^{-6} mutations/Mb) of MSI tumors, most with *MLH1* promoter methylation; 3) a group with lower mutation frequency (2.9×10^{-6} mutations/Mb) and most of the microsatellite stable (MSS) endometrioid cancers; and 4) a group that consists primarily of serous-like cancers with extensive SCNA (copy-number cluster 4) and a low mutation rate (2.3×10^{-6} mutations/Mb). The ultra-mutated group consisted of 17 (7%) tumors exemplified by an increased C→A transversion frequency, all with mutations in the exonuclease domain of *POLE*, and an improved progression-free survival (Fig. 2a and 2c). *POLE* is a catalytic subunit of DNA polymerase epsilon involved in nuclear DNA replication and repair. We identified hotspot mutations in *POLE* at P286R and V411L present in 13 (76%) of the 17 ultramutated samples. Significantly mutated genes (SMGs) identified at low False Discovery Rates (Q) in this subset included *PTEN* (at 94% with $Q = 0$), *PIK3R1* (65%, $Q = 8.3 \times 10^{-7}$), *PIK3CA* (71%, $Q = 9.1 \times 10^{-5}$), *FBXW7* (82%, $Q = 1.4 \times 10^{-4}$), *KRAS* (53%, $Q = 9.2 \times 10^{-4}$), and *POLE* (100%, $Q = 4.2 \times 10^{-3}$). Mutation rates in *POLE* mutant endometrial and previously reported ultramutated colorectal tumors exceed that found in any other lineage including lung cancer and melanoma.^{15–17} Germline susceptibility variants have been reported in

POLE (L424V) and *POLD1* (S478N), but were not found in our endometrial normal exome-seq reads.¹⁸

The MSI endometrioid tumors had a mutation frequency approximately 10-fold greater than MSS endometrioid tumors, few SCNAs, frame-shift deletions in *RPL22*, frequent non-synonymous *KRAS* mutations, and few mutations in *FBXW7*, *CTNNB1*, *PPP2R1A*, and *TP53*. The MSS, copy number low, endometrioid tumors had an unusually high frequency of *CTNNB1* mutations (52%); the only gene with a higher mutation frequency than the MSI samples. The copy number high group contained all of the remaining serous cases and one-quarter of the grade 3 endometrioid cases. Most of these tumors had *TP53* mutations and a high frequency of *FBXW7* (22%, $Q=0$) and *PPP2R1A* (22%, $Q=1.7\times 10^{-16}$) mutations, previously reported as common in uterine serous but not endometrioid carcinomas. Thus, a subset of high-grade endometrioid tumors had similar SCNAs and mutation spectra as uterine serous carcinomas, suggesting these patients might benefit from treatment approaches that parallel those for serous tumors.

There were 48 genes with differential mutation frequencies across the four groups (Fig. 2d, Supplementary Data File S3.1). *ARID5B*, a member of the same AT-rich interaction domain (ARID) family as *ARID1A*, was more frequently mutated in MSI (23.1%), than in either MSS endometrioid (5.6%) or high SCNA serous tumors (0%), a novel finding for endometrial cancer. Frame-shifting *RPL22* indels near a homopolymer at Lys15 were almost exclusively found in the MSI group (36.9%). The *TP53* mutation frequency (>90%) in serous tumors differentiates them from the endometrioid subtypes (11.4%). However, many (10 of 20; 50%) endometrioid tumors with a non-silent *TP53* mutation also had non-silent mutations in *PTEN*, compared to only 1 of 39 (2.6%) serous tumors with *TP53* non-silent mutations. Though *TP53* mutations are not restricted to serous tumors, the co-existing *PTEN* mutations in the endometrioid cases suggest a distinct tumorigenic mechanism.

Comparisons of 66 SMGs between traditional histologic subtypes are provided (Supplementary Methods S3) and SMGs across other subcohorts can be found in Supplementary Data File S3.2. The spectrum of *PIK3CA* and *PTEN* mutations in endometrial cancer also differs from other solid tumors (Supplementary Methods S3). Integrated analysis may be useful for identifying histologically misclassified cases. For example, a single serous case was identified without a *TP53* mutation or extensive SCNA and with a *KRAS* mutation and high mutation rate. Upon re-review of the histologic section, the case was deemed consistent with a grade 3 endometrioid tumor demonstrating how molecular analysis could reclassify tumor histology and potentially impact treatment decisions.

Multiplatform subtype classifications

All of the endometrial tumors were examined for mRNA expression (n=333), protein expression (n=293), miRNA expression (n=367), and DNA methylation (n=373) (Supplementary Methods S4–S7). Unsupervised k-means clustering of mRNA expression from RNA sequencing identified three robust clusters termed ‘mitotic’, ‘hormonal’, and ‘immunoreactive’ (Supplementary Fig. 4.1) that were significantly correlated with the four integrated clusters; *POLE*, MSI, CN low and CN high ($P<0.0001$). Supervised analysis

identified signature genes of the *POLE* cluster ($n = 17$) mostly involved in cellular metabolism (Fig. 3a). Among the few signature genes in the MSI cluster was decreased *MLH1* mRNA expression likely due to its promoter methylation. Elevated progesterone receptor (*PGR*) expression was noted in the CN low cluster, suggesting responsiveness to hormonal therapy. The CN high cluster, which included most serous and serous-like endometrioid tumors, exhibited the greatest transcriptional activity exemplified by increased cell cycle deregulation (e.g. *CCNE1*, *PIK3CA*, *MYC*, and *CDKN2A*) and *TP53* mutation (Supplementary Figs. 4.2 and 4.3). This is consistent with reports that elevated *CDKN2A* can distinguish serous from endometrioid carcinomas.¹⁹ Approximately 85% of cases in the CN high cluster shared membership with the ‘mitotic’ mRNA subtype.

Supervised clustering of the RPPA expression data was consistent with loss of function for many of the mutated genes (Fig. 3b). *TP53* was frequently mutated in the CN high group ($P=2.5\times 10^{-27}$) and its protein expression was also elevated, suggesting these mutations are associated with increased expression. By contrast, *PTEN* ($P=2.8\times 10^{-19}$) and *ARID1A* ($P=1.2\times 10^{-6}$) had high mutation rates in the remaining groups, but their expression was decreased, suggesting inactivating mutations in both genes. The CN high group also had decreased levels of phospho-AKT, consistent with down regulation of the AKT pathway. The CN low group had elevated *RAD50* expression, which is associated with DNA repair, explaining some of the differences between the CN high and CN low groups. The *POLE* group had high expression of *ASNS* and *CCNB1*, whereas the MSI tumors had both high phospho-AKT and low *PTEN* expression.

Unsupervised clustering of DNA methylation data generated from Illumina Infinium DNA methylation arrays revealed four unique subtypes (MC1-4) that support the four integrative clusters. A heavily methylated subtype (MC1) reminiscent of the CpG island methylator phenotype (CIMP) phenotype described in colon cancers and glioblastomas,^{20–22} was associated with the MSI subtype and attributable to promoter hypermethylation of *MLH1*. A serous-like cluster (MC3) with minimal DNA methylation changes was composed primarily of serous tumors and some endometrioid tumors (Supplementary Fig. 7.1) and contained most of the CN high tumors.

Integrative clustering using the iCluster framework returned two major clusters split primarily on serous and endometrioid histology highlighting *TP53* mutations, lack of *PTEN* mutation and encompassing almost exclusively CN high tumors (Supplementary Fig. 8.1).²³ We developed a new clustering algorithm, called SuperCluster, to derive overall subtypes based on sample cluster memberships across all data types (Supplementary Fig. 9.1). SuperCluster identified 4 clusters that generally confirmed the contributions of individual platforms to the overall integrated clusters. No major batch effects were identified for any platform (Supplementary Methods S10).

Structural Aberrations

To identify somatic chromosomal aberrations, we performed low-pass, paired-end, whole-genome sequencing on 106 tumors with matched normals. We found recurrent translocations involving genes in several pathways including WNT, EGFR-RAS-MAPK, PI3K, Protein Kinase A, RB and apoptosis. The most frequent translocations (5/106)

involved a member of the BCL family (*BCL2*, *BCL7*, *BCL9* and *BCL2L11*). Four of these were confirmed by identification of the translocation junction point and two were also confirmed by RNA-Seq. In all cases the translocations result in in-frame fusions and predicted to result in activation or increased expression of the BCL family members (Supplementary Fig. 3.2). Translocations involving members of the BCL family leading to reduced apoptosis have been described in other tumor types²⁴ and our results suggest that similar mechanisms may be operative here.

Pathway alterations

Multiple platform data were integrated to identify recurrently altered pathways in the four endometrial cancer integrated subgroups. Because of the high background mutation rate and small sample size, we excluded the *POLE* subgroup from this analysis. Considering all recurrently mutated, homozygously deleted, and amplified genes, we used MEMo²⁵ to identify gene networks with mutually exclusive alteration patterns in each subgroup. The most significant module was found in the CN low group and contained *CTNNB1*, *KRAS*, and *SOX17* (Fig. 4a). The very strong mutual exclusivity between mutations in these three genes suggests that alternative mechanisms activate WNT signaling in endometrioid endometrial cancer. Activating *KRAS* mutations have been shown to increase the stability of beta-catenin via GSK3beta leading to an alternative mechanism of beta-catenin activation to APC degradation.²⁶ *SOX17*, which mediates proteasomal degradation of beta-catenin,^{27,28} is mutated exclusively in the CN low group (8%) at recurrent positions (A96G and S403I) not previously described. Other genes with mutually exclusive alteration patterns in this module were *FBXW7*, *FGFR2*, and *ERBB2*.²⁹ *ERBB2* was focally amplified with protein overexpression in 25% of the serous or serous-like tumors, suggesting a potential role for HER2 targeted inhibitors. A small clinical trial of trastuzumab found no activity in endometrial carcinoma, but accrued few HER2 FISH-amplified serous carcinomas.³⁰

PIK3CA and *PIK3R1* mutations were frequent and showed a strong tendency for mutual exclusivity in all subgroups, but unlike other tumor types, they co-occurred with *PTEN* mutations in the MSI and CN low subgroups as previously reported (Fig. 4b).^{5,9} The CN high subgroup showed mutual exclusivity between alterations of all three genes. Overall, 93% of endometrioid tumors had mutations that suggested potential for targeted therapy with PI3K/AKT pathway inhibitors.

Consensus clustering of copy number, mRNA expression, and pathway interaction data for 324 samples yielded 5 PARADIGM clusters with distinct pathway activation patterns (Fig. 4c, Supplementary Methods, S11).³¹ Paradigm cluster 1 had the lowest level of MYC pathway activation and highest level of WNT pathway activation, consistent with its composition of CN low cases having frequent *CTNNB1* mutations. PARADIGM cluster 3 was composed predominantly of the CN high cases with relatively high MYC/Max but low ER/FOXA1 signaling and p53 activity. Only *TP53* truncation and not missense mutations were implicated as loss-of-function mutations, suggesting different classes of p53 mutations may have distinct signaling consequences. Paradigm cluster 5 was enriched for hormone receptor expression.

Comparison to ovarian and breast cancers

The clinical and pathologic features of uterine serous carcinoma and high-grade serous ovarian carcinoma (HGSOC) are quite similar. HGSOC shares many similar molecular features with basal-like breast carcinoma.³² Focal SCNA patterns were similar between these three tumor subtypes and unsupervised clustering identified relatedness (Fig. 5a, Supplementary Fig. 12.1). Supervised analysis of transcriptome datasets showed high correlation between tumor subtypes (Supplementary Fig. 12.2). The MC3 DNA methylation subtype with minimal DNA methylation changes also was similar to basal-like breast and HGSOCs (Supplementary Fig. 12.3). High frequency of *TP53* mutations is shared across these tumor subtypes (uterine serous, 91%; ovarian serous, 96%; basal-like breast, 84%),^{33,34} as is the very low frequency of *PTEN* mutations (uterine serous carcinoma, 2%; HGSOC, 1%; basal-like breast carcinoma, 1%). Differences include a higher frequency of *FBXW7*, *PPP2R1A*, and *PIK3CA* mutations in uterine serous compared to basal-like breast and HGSOCs (Fig. 5b). We show that uterine serous carcinomas share many molecular features with both HGSOC and basal-like breast carcinomas, despite more frequent mutations, suggesting new opportunities for overlapping treatment paradigms.

Discussion

This integrated genomic and proteomic analysis of 373 endometrial cancers provides insights into disease biology and diagnostic classification that could have immediate therapeutic application. Our analysis identified four novel groups of tumors based on integrated genomic data, including a novel *POLE* subtype in ~10% of endometrioid tumors. Ultra-high somatic mutation frequency, MSS, and common, newly identified hotspot mutations in the exonuclease domain of *POLE* characterize this subtype. SCNAs add a layer of resolution, revealing that most endometrioid tumors have few SCNAs, most serous and serous-like tumors exhibit extensive SCNAs, and the extent of SCNA roughly correlates with PFS.

Endometrial cancer has more frequent mutations in the PI3K/AKT pathway than any other tumor type studied by TCGA to-date. Endometrioid endometrial carcinomas share many characteristics with colorectal carcinoma including a high frequency of MSI (40% and 11%, respectively), *POLE* mutations (7% and 3%, respectively) leading to ultrahigh mutation rates, and frequent activation of WNT/CTNNB1 signaling; yet endometrial carcinomas have novel exclusivity of *KRAS* and *CTNNB1* mutation and a distinct mechanism of pathway activation. Uterine serous carcinomas share many similar characteristics with basal-like breast and HGSOCs; three tumor types with a high frequency non-silent *TP53* mutations and extensive SCNA. However, the high frequency of *PIK3CA*, *FBXW7*, *PPP2R1A*, and *ARID1A* mutations in uterine serous carcinoma are not found in basal-like breast and HGSOCs. The frequency of mutations in *PIK3CA*, *FBXW7*, and *PPP2R1A* was ~30% higher than in a recently reported study of 76 uterine serous carcinomas,¹¹ but similar to another study.¹² Uterine serous carcinomas have *ERBB2* amplification in 27% of tumors and *PIK3CA* mutations in 42%, which provide translational opportunities for targeted therapeutics.

Early stage Type I endometrioid tumors are often treated with adjuvant radiotherapy, while similarly staged Type II serous tumors are treated with chemotherapy. High-grade serous and endometrioid endometrial carcinomas are difficult to correctly subtype, and intra-observer concordance among specialty pathologists is low.^{7,34–36} Our molecular characterization data demonstrate that ~25% of tumors classified as high-grade endometrioid by pathologists have a molecular phenotype similar to uterine serous carcinoma, including frequent *TP53* mutations and extensive SCNA. The compelling similarities between this subset of endometrioid tumors and uterine serous carcinomas suggest that genomic-based classification may lead to improved management of these patients. Clinicians should carefully consider treating copy number altered endometrioid patients with chemotherapy rather than adjuvant radiotherapy and formally test such hypotheses in prospective clinical trials. Further, the marked molecular differences between endometrioid and serous-like tumors suggest that these tumors warrant separate clinical trials to develop the independent treatment paradigms that have improved outcomes in other tumor types, such as breast cancer.

Methods Summary

Biospecimens were obtained from 373 patients after institutional review board-approved consents. DNA and RNA were co-isolated using a modified AllPrep kit (Qiagen). We used Affymetrix SNP 6.0 microarrays to detect SCNA in 363 samples and GISTIC analysis to identify recurrent events.³⁷ The exomes of 248 tumors were sequenced to a read-depth of at least 20×. We performed low-pass whole-genome sequencing on 107 tumors to a mean depth of 6×. Consensus clustering was used to analyze mRNA, miRNA, RPPA, and methylation data with methods previously described.^{38–40} Integrated cross-platform analyses were performed using MEMo, iCluster, and PARADIGM.^{25,31}

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We wish to thank all patients and families who contributed to this study. We thank M. Sheth and L. Lund for administrative coordination of TCGA activities, G. Monemvasitis for editing the manuscript, and C. Gunter for critical reading of the manuscript. This work was supported by the following grants from the USA National Institutes of Health: 5U24CA143799-04, 5U24CA143835-04, 5U24CA143840-04, 5U24CA143843-04, 5U24CA143845-04, 5U24CA143848-04, 5U24CA143858-04, 5U24CA143866-04, 5U24CA143867-04, 5U24CA143882-04, 5U24CA143883-04, 5U24CA144025-04, U54HG003067, U54HG003079, and U54HG003273.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin.* 2012; 62:10–29. [PubMed: 22237781]
2. Fleming GF, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. *J Clin Oncol.* 2004; 22:2159–2166. [PubMed: 15169803]

3. Sutton G, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. *Gynecol Oncol.* 2005; 97:755–763. [PubMed: 15913742]
4. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. *Verh Dtsch Ges Pathol.* 1997; 81:228–232. [PubMed: 9474874]
5. Cheung LW, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. *Cancer discovery.* 2011; 1:170–185. [PubMed: 21984976]
6. Levine RL, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. *Cancer research.* 1998; 58:3254–3258. [PubMed: 9699651]
7. McConechy MK, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. *J Pathol.* 2012; 228:20–30. [PubMed: 22653804]
8. Byron SA, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. *PLoS One.* 2012; 7:e30801.10.1371/journal.pone.0030801 [PubMed: 22383975]
9. Urick ME, et al. PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. *Cancer research.* 2011; 71:4061–4067. [PubMed: 21478295]
10. Zigelboim I, et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. *J Clin Oncol.* 2007; 25:2042–2048. [PubMed: 17513808]
11. Kuhn E, et al. Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses. *J Natl Cancer Inst.* 2012; 104:1503–1513. [PubMed: 22923510]
12. Le Gallo M, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. *Nat Genet.* 2012; 44:1038–1045. [PubMed: 22455]
13. Salvesen HB, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. *Proceedings of the National Academy of Sciences of the United States of America.* 2009; 106:4834–4839. [PubMed: 19261849]
14. Cowin PA, et al. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. *Cancer research.* 2012; 72:4060–4073. [PubMed: 22896685]
15. Comprehensive molecular characterization of human colon and rectal cancer. *Nature.* 2012; 487:330–337. [PubMed: 22810696]
16. Govindan R, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. *Cell.* 2012; 150:1121–1134. [PubMed: 22980976]
17. Pleasance ED, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature.* 2010; 463:191–196. [PubMed: 20016485]
18. Palles C, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat Genet.* 2012; 45:136–144. [PubMed: 23263490]
19. Bartosch C, et al. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. *Adv Anat Pathol.* 2011; 18:415–437. [PubMed: 21993268]
20. Toyota M, et al. CpG island methylator phenotype in colorectal cancer. *Proceedings of the National Academy of Sciences of the United States of America.* 1999; 96:8681–8686. [PubMed: 10411935]
21. Hinoue T, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. *Genome Res.* 2012; 22:271–282. [PubMed: 21659424]
22. Noushmehr H, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell.* 2010; 17:510–522. [PubMed: 20399149]

23. Shen R, Olshen AB, Ladanyi M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. *Bioinformatics*. 2009; 25:2906–2912. [PubMed: 19759197]
24. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature*. 1990; 348:334–336. [PubMed: 2250705]
25. Ciriello G, Cerami E, Sander C, Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. *Genome Res*. 2012; 22:398–406. [PubMed: 21908773]
26. Li J, Mizukami Y, Zhang X, Jo WS, Chung DC. Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. *Gastroenterology*. 2005; 128:1907–1918. [PubMed: 15940626]
27. Zorn AM, et al. Regulation of Wnt signaling by Sox proteins: XSox17 alpha/beta and XSox3 physically interact with beta-catenin. *Mol Cell*. 1999; 4:487–498. [PubMed: 10549281]
28. Sinner D, et al. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. *Mol Cell Biol*. 2007; 27:7802–7815. [PubMed: 17875931]
29. Pollock PM, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. *Oncogene*. 2007; 26:7158–7162. [PubMed: 17525745]
30. Fleming GF, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2010; 116:15–20. [PubMed: 19840887]
31. Vaske CJ, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. *Bioinformatics*. 2010; 26:i237–245. [PubMed: 20529912]
32. Comprehensive molecular portraits of human breast tumours. *Nature*. 2012; 490:61–70. [PubMed: 23000897]
33. Integrated genomic analyses of ovarian carcinoma. *Nature*. 2011; 474:609–615. [PubMed: 21720365]
34. Clarke BA, Gilks CB. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. *J Clin Pathol*. 2010; 63:410–415. [PubMed: 20418232]
35. Yemelyanova A, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. *Am J Surg Pathol*. 2009; 33:1504–1514. [PubMed: 19623034]
36. Gilks CB, EO, Soslow RA. Poor Inter-Observer Reproducibility in the Diagnosis of High-Grade Endometrial Carcinoma. *Am J Surg Pathol*. 2012 in press.
37. Mermel CH, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biol*. 2011; 12:R41. [PubMed: 21527027]
38. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. *BMC bioinformatics*. 2010; 11:367. [PubMed: 20598126]
39. Houseman EA, et al. Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributions. *BMC bioinformatics*. 2008; 9:365. [PubMed: 18782434]
40. Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. *Proceedings of the National Academy of Sciences of the United States of America*. 2004; 101:4164–4169. [PubMed: 15016911]

Appendix

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
Dr.	Christopher	Adams	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
Mr.	Thomas	Barr	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Mr.	Aaron D.	Black	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Mr.	Jay	Bowen	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Mr.	John	Deardurff	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Ms.	Jessica	Frick	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Dr.	Julie M.	Gastier-Foster	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	The Ohio State University, Columbus, OH 43210
Mr.	Thomas	Grossman	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Ms.	Hollie A.	Harper	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Ms.	Melissa	Hart-Kothari	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Ms.	Carmen	Helsel	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Mr.	Aaron	Hobensack	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Ms.	Harkness	Keck	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Ms.	Kelley	Kneile	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Ms.	Kristen M.	Leraas	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Ms.	Tara M.	Lichtenberg	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Ms.	Cynthia	McAllister	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Dr.	Robert E.	Pyatt	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Dr.	Nilsa C.	Ramirez	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	The Ohio State University, Columbus, OH 43210
Ms.	Teresa R.	Tabler	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Mr.	Nathan	Vanhoose	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Dr.	Peter	White	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Ms.	Lisa	Wise	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Dr.	Erik	Zmuda	The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Ms.	Brenda	Ayala	SRA International, Fairfax, VA, USA	
Ms.	Anna L.	Chu	SRA International, Fairfax, VA, USA	
Dr.	Mark A.	Jensen	SRA International, Fairfax, VA, USA	
Dr.	Prachi	Kothiyal	SRA International, Fairfax, VA, USA	

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
Dr.	Todd D.	Pihl	SRA International, Fairfax, VA, USA	
Dr.	Joan	Pontius	SRA International, Fairfax, VA, USA	
Dr.	David A.	Pot	SRA International, Fairfax, VA, USA	
Dr.	Eric E.	Snyder	SRA International, Fairfax, VA, USA	
Mr.	Deepak	Srinivasan	SRA International, Fairfax, VA, USA	
Dr.	Ari B.	Kahn	SRA International, Fairfax, VA, USA	
Dr.	Daphne W.	Bell	Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA	
Dr.	Pamela	Pollock	Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, 4059, Australia	
Dr.	Chen	Wang	Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905	
Dr.	David A.	Wheeler	HumanGenomeSequencing Center, Baylor College of Medicine, Houston, Texas 77030,	
Dr.	Eve	Shinbrot	HumanGenomeSequencing Center, Baylor College of Medicine, Houston, Texas 77030,	
Dr.	Beth Y.	Karlan	Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA	
Dr.	Andrew	Berchuck	Duke University Medical Center, Duke Cancer Institute, Durham, NC 27710	
Dr.	Sean C.	Dowdy	Department of OB Gyn, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN 55905	
Dr.	Boris	Winterhoff	Department of OB Gyn, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN 55905	
Dr.	Inanc	Birol	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Mr.	Yaron S.N.	Butterfield	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Ms.	Rebecca	Carlsen	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Ms.	Candace	Carter	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Mr.	Andy	Chu	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Mr.	Eric	Chuah	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Ms.	Hye-Jung E.	Chun	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Ms.	Noreen	Dhalla	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Mr.	Ranabir	Guin	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
Ms.	Carrie	Hirst	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Dr.	Robert A.	Holt	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Prof.	Steven J.M.	Jones	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Ms.	Darlene	Lee	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Ms.	Haiyan I.	Li	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Prof.	Marco A.	Marra	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Mr.	Michael	Mayo	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Dr.	Richard A.	Moore	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Dr.	Andrew J.	Mungall	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Mr.	Patrick	Plettner	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Ms.	Jacqueline E.	Schein	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Ms.	Payal	Sipahimalani	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Ms.	Angela	Tam	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Mr.	Richard J.	Varhol	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Dr.	A. Gordon	Robertson	Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada	
Dr.	Angela	Hadjipanayis	Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA	
Dr.	Semin	Lee	Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115	
Mr.	Harshad S.	Mahadeshwar	Institute for Applied Cancer Science, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054	
Dr.	Peter	Park	Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115	Informatics Program, Boston Children's Hospital, Boston, MA 02115

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
Dr.	Alexei	Protopopov	Institute for Applied Cancer Science, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054	
Ms.	Xiaojia	Ren	Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA	
Mr.	Sahil	Seth	Institute for Applied Cancer Science, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054	
Dr.	Xingzhi	Song	Institute for Applied Cancer Science, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054	
Dr.	Jiabin	Tang	Institute for Applied Cancer Science, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054	
Dr.	Ruibin	Xi	Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115	
Dr.	Lixing	Yang	Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115	
Mr.	Dong	Zeng	Institute for Applied Cancer Science, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054	
Dr.	Jianhua	Zhang	Institute for Applied Cancer Science, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054	
Dr.	Kristin	Ardlie	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Dr.	Scott	Carter	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Mr.	Jeff	Gentry	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Mr.	Bryan	Hernandez	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Dr.	Matthew	Meyerson	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Mr.	Robert	Onofrio	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Dr.	Gordon	Saksena	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Mr.	Steven E.	Schumacher	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Dr.	Barbara	Tabak	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Dr.	Wendy	Winckler	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
Dr.	Rameen	Beroukim	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Dr.	Itai	Pashtan	Harvard Radiation Oncology Program, Brigham and Womens Hospital, Boston, MA 02115	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.
Dr.	Helga B.	Salvesen	Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway	Department of Clinical Medicine, University of Bergen, Norway
Dr.	Andrew D.	Cherniack	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Dr.	Gad	Getz	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Dr.	Stacey B.	Gabriel	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Dr.	J. Todd	Auman	Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	Institute for Pharmacogenetics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA
Mr.	Saianand	Balu	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Mr.	Tom	Bodenheimer	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Ms.	Elizabeth	Buda	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Dr.	D. Neil	Hayes	Department of Internal Medicine, Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA
Mr.	Alan P.	Hoyle	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Dr.	Stuart R.	Jefferys	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Dr.	Corbin D.	Jones	Department of Biology, University of North Carolina at Chapel Hill, NC 27599 USA	

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
Dr.	Shaowu	Meng	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Dr.	Piotr A.	Mieczkowski	Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Mr.	Lisle E.	Mose	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Dr.	Joel S.	Parker	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Dr.	Charles M.	Perou	Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA
Dr.	Jeff	Roach	Research Computing Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Mrs.	Donghui	Tan	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Dr.	Michael D.	Topal	Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA
Dr.	Scot	Waring	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Mr.	Junyuan	Wu	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	
Dr.	Katherine A.	Hoadley	Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA
Dr.	Stephen B.	Baylin	Cancer Biology Division, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland 21231, USA.	
Mr.	Moiz S.	Bootwalla	University of Southern California Epigenome Center, University of Southern California, Los Angeles, California, 90089, USA.	
Mr.	Phillip H.	Lai	University of Southern California Epigenome Center, University of Southern California, Los Angeles, California, 90089, USA.	
Mr.	Timothy J.	Triche, Jr.	University of Southern California Epigenome Center, University of Southern California, Los Angeles, California, 90089, USA.	
Dr.	David J.	Van Den Berg	University of Southern California Epigenome Center, University of Southern California, Los Angeles, California, 90089, USA.	

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
Dr.	Daniel J.	Weisenberger	University of Southern California Epigenome Center, University of Southern California, Los Angeles, California, 90089, USA.	
Dr.	Peter W.	Laird	University of Southern California Epigenome Center, University of Southern California, Los Angeles, California, 90089 USA.	
Ms.	Hui	Shen	University of Southern California Epigenome Center, University of Southern California, Los Angeles, California, 90089, USA.	
	Juok	Cho	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
	Daniel	DiCara	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
	Scott	Frazer	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
	David	Heiman	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
	Rui	Jing	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
	Pei	Lin	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
	Will	Mallard	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
	Petar	Stojanov	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
	Doug	Voet	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
	Hailei	Zhang	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Dr.	Lihua	Zou	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
	Michael	Noble	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Dr.	Sheila M.	Reynolds	Institute for Systems Biology, Seattle, Washington 98109, USA	
Dr.	Ilya	Shmulevich	Institute for Systems Biology, Seattle, Washington 98109, USA	
Dr.	Wei	Zhang	University of Texas MD Anderson Cancer Center, Houston, TX 77054	
Mr.	B. Arman	Aksoy	Computational Biology Center, Memorial Sloan- Kettering Cancer Center, New York, New York 10065, USA.	
Mr.	Yevgeniy	Antipin	Computational Biology Center, Memorial Sloan- Kettering Cancer Center, New York, New York 10065, USA.	

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
Dr.	Giovanni	Ciriello	Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.	
Mr.	Gideon	Dresdner	Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.	
Dr.	Jianjiong	Gao	Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.	
Dr.	Benjamin	Gross	Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA. Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York	
Dr.	Rileen	Sinha	Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.	
Mr.	S. Onur	Sumer	Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.	
Dr.	Barry S.	Taylor	Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158	
Dr.	Ethan	Cerami	Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.	
Dr.	Nils	Weinhold	Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.	
Dr.	Nikolaus	Schultz	Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.	
Dr.	Ronglai	Shen	Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 USA	
Mr.	Matti	Annala	University of Texas MD Anderson Cancer Center, Houston, TX 77054	Tampere University of Technology Korkeakoulunkatu 10, FI-33720 Tampere, Finland
Dr.	Bradley M.	Broom	Dept. of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA	
Mr.	Tod D.	Casasent	Dept. of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA	
Dr.	Zhenlin	Ju	Dept. of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA	
Dr.	Han	Liang	Dept. of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA	
Dr.	Guoyan	Liu	University of Texas MD Anderson Cancer Center, Houston, TX 77054	
Dr.	Yiling	Lu	Dept. of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA	

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
Ms.	Anna K.	Unruh	Dept. of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA	
Mr.	Chris	Wakefield	Dept. of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA	
Dr.	John N.	Weinstein	Dept. of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA	
Dr.	Nianxiang	Zhang	Dept. of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA	
Dr.	Yuexin	Liu	University of Texas MD Anderson Cancer Center, Houston, TX 77054	
Dr.	Russell	Broadus	Dept. of Pathology, Unit 85 University of Texas M.D. Anderson Cancer Center 1515 Holcombe Blvd. Houston, Texas 77030	
Dr.	Rehan	Akbani	Dept. of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA	
Dr.	Gordon B.	Mills	Dept. of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA	
Dr.	Stephen	Benz	Department of Biomolecular Engineering and Center for Biomolecular Science and Engineering, University of California Santa Cruz, Santa Cruz, CA 95064, USA	
Mr.	Ted	Goldstein	Department of Biomolecular Engineering and Center for Biomolecular Science and Engineering, University of California Santa Cruz, Santa Cruz, CA 95064, USA	
Dr.	David	Haussler	Department of Biomolecular Engineering and Center for Biomolecular Science and Engineering, University of California Santa Cruz, Santa Cruz, CA 95064, USA	
Mr.	Sam	Ng	Department of Biomolecular Engineering and Center for Biomolecular Science and Engineering, University of California Santa Cruz, Santa Cruz, CA 95064, USA	
Mr.	Christopher	Szeto	Department of Biomolecular Engineering and Center for Biomolecular Science and Engineering, University of California Santa Cruz, Santa Cruz, CA 95064, USA	
Dr.	Joshua	Stuart	Department of Biomolecular Engineering and Center for Biomolecular Science and Engineering, University of California Santa Cruz, Santa Cruz, CA 95064, USA	
Dr.	Christopher C	Benz	Buck Institute for Age Research, Novato, California 94945, USA	
Dr.	Christina	Yau	Buck Institute for Age Research, Novato, California 94945, USA	
	Kristian	Cibulskis	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Dr.	Eric	Lander	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Dr.	Andrey	Sivachenko	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
	Carrie	Sougnez	The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.	
Ms.	Michelle	O'Laughlin	The Genome Institute, Washington University, St. Louis, MO 63108	
Ms.	Heather	Schmidt	The Genome Institute, Washington University, St. Louis, MO 63108	
Dr.	Richard K.	Wilson	The Genome Institute, Washington University, St. Louis, MO 63108	
Dr.	Kai	Ye	The Genome Institute, Washington University, St. Louis, MO 63108	
Dr.	Li	Ding	The Genome Institute, Washington University, St. Louis, MO 63108	
Dr.	Cyriac	Kandoth	The Genome Institute, Washington University, St. Louis, MO 63108	
Dr.	Elaine R.	Mardis	The Genome Institute, Washington University, St. Louis, MO 63108	
Dr.	Greg	Eley	Scimentis, LLC, Atlanta, GA 30666 USA	
Dr.	Martin L.	Ferguson	MLF Consulting, Arlington, Maryland 02474, USA	
Dr.	Tanja	Davidson	The Cancer Genome Atlas Program Office, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA	
Mr.	John A.	Demchok	The Cancer Genome Atlas Program Office, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA	
Dr.	Kenna R.	Mills Shaw	The Cancer Genome Atlas Program Office, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA	
Ms.	Margi	Sheth	The Cancer Genome Atlas Program Office, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA	
Dr.	Liming	Yang	The Cancer Genome Atlas Program Office, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA	
Dr.	Mark S.	Guyer	National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA	
Dr.	Bradley A.	Ozenberger	National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA	
Dr.	Heidi J.	Sofia	National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA	
Dr.	Nandita	Barnabas	Asterand, Detroit, MI 48202	
Ms.	Charlenia	Berry-Green	Asterand, Detroit, MI 48202	
Dr.	Victoria	Blanc	Asterand, Detroit, MI 48202	
Ms.	Lori	Boice	University of North Carolina, Chapel Hill, NC 27599	
Mr.	Michael	Button	Asterand, Detroit, MI 48202	
Mr.	Adam	Farkas	Asterand, Detroit, MI 48202	
Dr.	Alex	Green, MD.	Asterand, Detroit, MI 48202	
Ms.	Jean	MacKenzie	Asterand, Detroit, MI 48202	
Ms.	Dana	Nicholson	Asterand, Detroit, MI 48202	
Mr.	Steve E.	Kalloger	OvCaRe British Columbia, British Columbia Cancer Agency, Vancouver British Columbia V5Z 4E6	The University of British Columbia Department of Pathology &

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
				Laboratory Medicine Vancouver, British Columbia V6T 2B5
Dr.	C. Blake	Gilks	OvCaRe British Columbia, British Columbia Cancer Agency, Vancouver British Columbia V5Z 4E6	The University of British Columbia Department of Pathology & Laboratory Medicine Vancouver, British Columbia V6T 2B5
Mrs.	Jenny	Lester	Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA	
Dr.	Sandra	Orsulic	Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA	
Dr	mark	borowsky	Helen F Graham Cancer Center at Christiana Care, Newark, DE,19713	
Dr	mark	cadungog	Helen F Graham Cancer Center at Christiana Care, Newark, DE,19713	
	christine	czerwinski	Helen F Graham Cancer Center at Christiana Care, Newark, DE,19713	
	lori	huelsenbeck-Dill	Helen F Graham Cancer Center at Christiana Care, Newark, DE,19713	
Dr	mary	iacocca	Helen F Graham Cancer Center at Christiana Care, Newark, DE,19713	
Dr	nicholas	petrelli	Helen F Graham Cancer Center at Christiana Care, Newark, DE,19713	
	brenda	rabeno	Helen F Graham Cancer Center at Christiana Care, Newark, DE,19713	
Dr	gary	witkin	Helen F Graham Cancer Center at Christiana Care, Newark, DE,19713	
Dr.	Elena	Nemirovich-Danchikova	Cureline, Inc., South San Francisco, CA 94080	
Dr.	Olga	Potapova	Cureline, Inc., South San Francisco, CA 94080	
Dr.	Daniil	Rotin	Cureline, Inc., South San Francisco, CA 94080	
Dr.	Michael	Birrer	Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA 02114	
Dr.	Phillip	DiSaia	University of California Medical Center, Irvine, Orange CA 92868 3298	
Mrs.	Laura	Monovich	GOG Tissue Bank, The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205	
Mrs.	Erin	Curley	International Genomics Consortium, Phoenix, AZ 85004	
Mrs.	Johanna	Gardner	International Genomics Consortium, Phoenix, AZ 85004	
Mr.	David	Mallery	International Genomics Consortium, Phoenix, AZ 85004	
Mr.	Attila	Teoman	Department of OB Gyn, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN 55905	
Mrs.	Faina	Bogomolny	Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065	

Dr.	First Name	Last Name	Institution #1 ADD ZIPCODE	Institution #2
Ms.	Fanny	Dao	Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065	
Dr.	Karuna	Garg	Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065	
Mr.	Narciso	Olvera	Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065	
Dr.	Robert A.	Soslow	Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065	
Dr.	Douglas A.	Levine	Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065	
Dr.	Mikhail	Abramov	N.N. Blokhin Russian Cancer Research Center RAMS, Moscow, Russia	
Dr.	John M.S.	Bartlett	Ontario Tumour Bank, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada	
Ms.	Sugy	Kodeeswaran	Ontario Tumour Bank, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada	
Dr.	Jeremy	Parfitt	Ontario Tumour Bank, London Health Sciences Centre, London, Ontario N6A 5A5, Canada	
Dr.	Fedor	Moiseenko	St. Petersburg Academic University, St. Petersburg, Russia	
Dr.	Blaise A.	Clarke	Department of Pathology, University Health Network, Toronto, Ontario M5G 2C4 Canada	
Dr.	Michael E.	Carney	University of Hawaii Cancer Center, Honolulu, HI 96813	
Dr.	Rayna K.	Matsuno	University of Hawaii, Honolulu HI 96813	
Ms.	Jennifer	Fisher	University of North Carolina, Chapel Hill, NC 27599	
Ms.	Mei	Huang	University of North Carolina, Chapel Hill, NC 27599	
Dr.	W. Kimryn	Rathmell	Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599	
Dr.	Leigh	Thorne	University of North Carolina, Chapel Hill, NC 27599	
Dr.	Linda	Van Le	University of North Carolina, Chapel Hill, NC 27599	
Dr.	Rajiv	Dhir	University of Pittsburgh, Pittsburgh PA 15213	
Dr.	Robert	Edwards	University of Pittsburgh, Pittsburgh PA 15213	
Dr.	Esther	Elishaev	University of Pittsburgh, Pittsburgh PA 15213	
Dr.	Kristin	Zorn	University of Pittsburgh, Pittsburgh PA 15213	
Dr.	Paul J.	Goodfellow	Washington University School of Medicine, St Louis, MO.	
Dr.	David	Mutch	Washington University School of Medicine, St Louis, MO.	




Figure 1. Somatic copy number alterations in endometrial carcinomas

a, Tumors were hierarchically clustered into four groups based on SCNAs. The heatmap shows SCNAs in each tumor (vertical axis) plotted by chromosomal location (horizontal axis). Vertical color bars to the right of the heatmap show genomic features. **b**, Kaplan-Meier curves of PFS for each copy number cluster.




Figure 2. Mutation spectra across endometrial carcinomas

a, Mutation frequencies (vertical axis, upper panel) plotted for each tumor (horizontal axis). Nucleotide substitutions are shown in the middle panel with a high frequency of C to A transversions in the samples with *POLE* exonuclease mutations. **b**, Tumors were stratified into the four groups by 1) nucleotide substitution frequencies and patterns, 2) MSI status, and 3) copy-number cluster. **c**, *POLE*-mutant tumors have significantly better PFS, while CN high tumors have the poorest outcome. **d**, Recurrently mutated genes are different between the four subgroups. Shown are the mutation frequencies of all genes that were significantly mutated in at least one of the four subgroups (MUSiC, FDR < 0.05, indicated by asterisk).




Figure 3. Gene expression across integrated subtypes in endometrial carcinomas
a, Supervised analysis of ~1500 genes significantly associated with integrated subtypes **b**, Heat map of protein expression clusters, supervised by integrated subtypes. Samples are in columns; genes or proteins are in rows.



Figure 4. Pathway alterations in endometrial carcinomas

a, The RTK/RAS/beta-catenin pathway is altered through multiple mechanisms that exhibit mutually exclusive patterns. Alteration frequencies are expressed as a percentage of all cases. The right panel shows patterns of occurrence. **b**, The PI3K pathway has mutually exclusive *PIK3CA* and *PIK3R1* alterations that frequently co-occur with *PTEN* alterations in the MSI and CN low subgroups. **c**, Heatmap display of top 1000 varying pathway features within PARADIGM consensus clusters. Samples were arranged in order of their consensus cluster membership. The mutation spectrum for each sample is displayed below the consensus clusters.




Figure 5. Genomic relationships between endometrial serous, ovarian serous, and basal-like breast carcinomas

a. Somatic copy number alterations for each tumor type. **b.** Frequency of genomic alterations present in at least 10% of one tumor type.